Product Information
DUPIXENT 200 MG/1.14 ML PEN is a brand product labeled by Sanofi-Aventis U.S. LLC, priced at $1778.8589 per ML under NDC 00024591902. Its NADAC has been published 124 times since May 22, 2024.
Strength
200 mg/1.14mL
Manufacturer
Sanofi-Aventis U.S. LLCNDC
00024591902
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
DUPILUMABApproval Type
Biologic (BLA)
FDA Application
BLA761055On Market Since
6/14/2021
Pharmacological Classes
Price Statistics
The NADAC for DUPIXENT 200 MG/1.14 ML PEN has been published 124 times since May 22, 2024, and over the history we have for it it has risen 11.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1778.8589 per ML |
|---|---|
| All-time high | $1779.3726 (Jun 10, 2026) |
| All-time low | $1601.8481 (May 22, 2024) |
| 52-week high | $1779.3726 |
| 52-week low | $1688.5632 |
| Median price | $1689.0095 |
| Average price | $1695.3720 |
| Largest weekly change | +5.0% (Jan 7, 2026) |
| Weeks tracked | 124 |
| Tracking since | May 22, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sanofi-Aventis U.S. LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Dupilumab market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DUPIXENT 200 MG/1.14 ML PEN?
The current National Average Drug Acquisition Cost (NADAC) for DUPIXENT 200 MG/1.14 ML PEN, manufactured by Sanofi-Aventis U.S. LLC, is $1778.8589 per ML (NDC 00024591902), effective Sep 30, 2026.
How has the price of DUPIXENT 200 MG/1.14 ML PEN changed over time?
Over the history we have for it, the NADAC for DUPIXENT 200 MG/1.14 ML PEN has risen 11.1%. It has been tracked across 124 weekly CMS publications since May 22, 2024.
What are the highest and lowest recorded NADAC prices for DUPIXENT 200 MG/1.14 ML PEN?
Since May 22, 2024, the NADAC for DUPIXENT 200 MG/1.14 ML PEN has ranged from a low of $1601.8481 (May 22, 2024) to a high of $1779.3726 (Jun 10, 2026), with a median of $1689.0095 per ML.
Are there cheaper alternatives to DUPIXENT 200 MG/1.14 ML PEN?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, DUPIXENT 200 MG/1.14 ML SYRING, is $1773.7351 per ML — about 0% below DUPIXENT 200 MG/1.14 ML PEN.
Who manufactures DUPIXENT 200 MG/1.14 ML PEN?
DUPIXENT 200 MG/1.14 ML PEN (NDC 00024591902) is labeled by Sanofi-Aventis U.S. LLC, and CMS classifies it as a brand product.